Gary C. Chang, Ph.D.
Affiliations: | University of Washington, Seattle, Seattle, WA |
Google:
"Gary Chang"Parents
Sign in to add mentor| Robert T. Paine | grad student | 2000 | University of Washington | |
| (Ecological interaction among natural enemies and its consequences for biological control.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Huang YH, Hsu KH, Chin CS, et al. (2021) The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma. Cancer Research and Treatment |
| Lee PH, Chen KC, Hsu KH, et al. (2021) Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients. Anti-Cancer Drugs |
| Huang YH, Hung JY, Ko HW, et al. (2021) The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. Therapeutic Advances in Medical Oncology. 13: 17588359211018022 |
| Su SF, Liu CH, Cheng CL, et al. (2021) Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses. Jco Precision Oncology. 5 |
| Park K, Chang GC, Curigliano G, et al. (2021) Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. Lung Cancer (Amsterdam, Netherlands). 155: 127-135 |
| Hsu KH, Huang JW, Tseng JS, et al. (2021) Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients. Oncotargets and Therapy. 14: 2139-2148 |
| Chang GC, Lam DC, Tsai CM, et al. (2021) Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. International Journal of Clinical Oncology |
| Wu SG, Chiang CL, Liu CY, et al. (2020) An Observational Study of Acquired T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. Frontiers in Oncology. 10: 1481 |
| Chih-Hsin Yang J, Camidge DR, Yang CT, et al. (2020) Safety, Efficacy and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-mutated Advanced NSCLC: a Multicenter, Open-label, Phase I Trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |
| Tseng JS, Hsu KH, Zheng ZR, et al. (2020) Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment. Oncology. 1-9 |